Congenital generalized lipodystrophy (CGL) is an autosomal recessive disorder characterized by extreme lack of body fat and severe insulin resistance since birth. Recently, mutations have been reported in 1-acylglycerol-3-phosphate-O-acyltransferase 2 (AGPAT2) and Berardinelli-Seip congenital lipodystrophy 2 (BSCL2 or Seipin) genes in affected subjects from pedigrees linked to chromosomes 9q34 and 11q13, respectively. The AGPAT2 catalyses the acylation of the lysophosphatidic acid at the sn-2 position to form phosphatidic acid, a key intermediate in the biosynthesis of triacylglycerol and glycerophospholipids. High expression of AGPAT2 mRNA in adipose tissue compared to other isoforms suggests that the mutations might affect the adipose tissue the most. The function of BSCL2 remains unknown. Several CGL pedigrees reveal no mutation in either of the above genes and are not linked to these loci, suggesting additional genetic loci for CGL. Thus, several distinct mechanisms can lead to extreme lack of adipose tissue in humans and cause CGL.
Introduction
Congenital generalized lipodystrophy (CGL, aka Berardinelli-Seip syndrome; OMIM # 269700) is a rare autosomal recessive disorder characterized by near complete absence of body fat and extreme insulin resistance since birth.
1,2 The patients with CGL also have severe acanthosis nigricans, hypertriglyceridemia and fatty liver and develop diabetes mellitus at an early age. They have extremely low serum leptin levels and have accelerated growth, and voracious appetite. Patients also show acromegaloid features and develop focal lytic lesions in the appendicular bones. Recent studies have revealed two genetic loci for CGL. [3] [4] [5] 
CGL1 LOCUS
Initial linkage studies by our group revealed a locus on chromosome 9q34. 3 Using additional markers between D9S1826 and D9S1838 further refined the region. 5 Several genes expressed in the region, which could be involved in adipocyte differentiation, proliferation, apoptosis and triacylglycerol (TG) biosynthesis, were evaluated including 1-acylglycerol-3-phosphate-O-acyltransferase 2 (AGPAT2).
Amplification of the exons for AGPAT2 in all affected subjects from a large consanguineous Portuguese pedigree revealed a small deletion spanning exons 3 and 4, indicating the disease causing gene. As shown in Figure 1a , various AGPAT2 mutations, including null, splice-site, frame-shift, insertion and deletion, have been found in several affected subjects.
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The IVS4-2A4G mutation was found to recur in pedigrees of African origin and the chromosomes carrying it had the same haplotype for seven SNPs within and around AGPAT2, indicating that this mutation is of ancestral origin. 5 AGPAT2, a 278 amino-acid protein, catalyses an essential acylation reaction in the biosynthesis of all glycerophospholipids and TG in eukaryotes (Figure 1b) . 9 Alignment of several acyltransferases revealed four blocks of conserved residues. 10 Further mutagenesis analysis of bacterial glycerol-3-phosphate acyltransferase (GPAT) revealed that two motifs, NHX 4 D and EGTR, are involved in the catalytic function of these enzymes. 11 The role of conserved motif NHX 4 D is further substantiated by the X-ray crystallographic analysis of highly conserved squash GPAT, showing that the phosphate group lies in the positively charged pocket created by histidine and aspartate. 12 The nature of the interaction between the various species of lysophosphatidic acid (LPA) and acyl-CoAs is unclear partly because the binary complex has not been studied. Study of various isoforms of AGPAT and other acyltransferases with different amino-and carboxy-terminal domains and of various missense mutations found in the AGPAT2 gene may improve the understanding of the structural requirement of the catalytic and substrate binding sites. The two well-characterized isoforms of AGPAT, AGPAT1 and AGPAT2 have 48% identity at the amino-acid level.
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Previous Northern blot analysis showed that AGPAT1 message is ubiquitously expressed in human tissues with the highest levels of expression in the skeletal muscle, whereas AGPAT2 expression is more tissue restricted with high levels in the liver and heart but almost undetectable in the brain. 9, 11 Our data reveal that AGPAT2 expression is at least two-fold higher than AGPAT1 in the normal human omental adipose tissue (Figure 1c ). 5 Furthermore, AGPAT2 is expressed at lower level in the liver and much less in the skeletal muscle compared to adipose tissue. Glycerol-3-phosphate (G-3-P) is the initial substrate that is acylated at sn-1 position by the enzyme glycerol-3-phosphate acyltransferase (GPAT) to form 1-acylglycerol-3-phosphate or lysophosphatidic acid (LPA). LPA is further acylated at sn-2 position by 1-acylglycerol-3-phosphate acyltransferase (AGPAT, aka lysophosphatidic acid acyltransferase LPAAT) to form PA. In the next step, phosphate group is removed by phosphatidate phosphohydrolase to produce diacylglycerol (DAG). DAG is further acylated at sn-3 position by diacylglycerol acyltransferase (DGAT) to produce TG. PA is required for PI synthesis. (c) Expression patterns of AGPAT1 and AGPAT2 isoforms in human omental adipose tissue, liver and muscle. Amplified AGPATs were normalized to the signal generated from G3PDH and expressed as arbitrary units, details in Agarwal et al. 5 (d) Schematic showing substrate specificities of AGPAT1 and 2. Using similar LPA, the two isoforms can produce different PAs. AGPAT1 may prefer C16:0 (palmitic acid, 16 carbon chain length with no double bond), whereas AGPAT2 may prefer C20:4 (arachidonic acid) for acylation at sn-2 position.
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In vitro experiments in cultured cells have shown that AGPAT2 prefers arachidonic acid for acylation at the sn-2 position of the glycerol (Figure 1d) . 13 Thus in patients with CGL1, the phosphatidic acid (PA) species with arachidonic acid may be absent in the tissues, although it is unclear if other AGPAT isoforms also prefer arachidonic acid and are upregulated. The differential expression pattern of AGPAT2 would suggest that the adipocyte would be affected the most. Since PA is the substrate for phosphatidylinositol (PI) synthesis, an important molecule involved in insulin signalling, reduced levels of or structurally different forms of PI in adipose tissue of patients with AGPAT2 mutations might cause insulin resistance. 14 The detailed investigations as to how mutations in AGPAT2 cause CGL1 are underway; however, it can be speculated that lipodystrophy occurs possibly due to lack of triglyceride synthesis in the adipocytes. Alternatively, reduced AGPAT2 activity could increase tissue levels of LPA, which may affect adipocyte functions. 15 LPA is a ligand for G protein-coupled receptors and may have a role in preadipocyte proliferation and adipogenesis. 16 Decreased AGPAT2 activity could also lead to reduced bioavailability of PA and phosphoglycerols (PI, phosphatidylcholine and phosphatidylethanolamine), which are important for membrane integrity and intracellular signalling and could affect adipocyte functions. Interestingly, homozygous deletion of the mitochondrial isoform of Gpat and of Dgat1 do not cause lipodystrophy in mice. 17, 18 However, other isoforms of these acyltransferases, although identified, have not been studied in detail.
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CGL2 LOCUS
The second CGL locus was found on chromosome 11q13 by Magre et al 4 and several mutations in BSCL2 (Seipin) gene have also been reported (Figure 2a) . 4, 8, 19 The mutation, F105fsX111, has been found to recur in patients of Lebanese origin, indicating a founder effect. BSCL2 gene encodes a 398 amino-acid protein, with no homology to any known protein, except to mouse Gng3lg. Thus, its function in adipose tissue biology remains unclear. Previous Northern blots have shown that the mRNA is widely expressed, with highest expression in the testes and brain. 8 Is there an additional genetic locus for CGL?
Most likely yes. Several pedigrees did not reveal mutations in both AGPAT2 and BSCL2 genes. 6, 8 The pedigrees identified by us and others do not link to 9q34 or 11q13 loci. 8, 20 Where available, the transcripts for AGPAT2 and BSCL2 appear to be normal. 8 
Summary
These observations show that a primary defect in adipose tissue metabolism can cause lipodystrophy and associated complications. Our observations also raise the possibility that other subtle defects in AGPATs may explain the relationship between insulin resistance and common forms of regional adiposity or abnormal body fat distribution. It is possible that upregulation of AGPATs in adipocytes might contribute to generalized obesity. Thus, the pharmacological inhibition of the AGPAT2 or other isoforms may be an approach to reduce adiposity. However, it is tied to the development of isoform-specific pharmacological agents, because different isoforms of the enzymes might have specific functions in human adipocytes. AGPAT2 and BSCL2 mutations in CGL AK Agarwal et al
